Management of Diabetes 

Diabetes is a metabolic disorder characterized by abnormal glucose metabolism. This generally results from either inadequate insulin production, target tissue resistance to insulin, or a combination of both. The essential manifestation of diabetes is elevated blood glucose.

I. Morbidity and mortality in diabetes is related to its acute and chronic complications:

A. Acute
  1. Diabetic ketoacidosis
  2. Hyperosmolar non-ketotic state
  3. Hypoglycemia
B. Chronic
   1. Retinopathy
   2. Nephropathy
   3. Neuropathy (peripheral and autonomic)
   4. Macrovascular disease (peripheral vascular disease, coronary artery disease, cerebrovascular disease)
   5. Foot complications (resulting from microvascular and macrovascular disease and neuropathy)

C. Diabetes is classified as type 1 or type 2 based on the presence or absence of endogenous insulin production. Diagnosis of diabetes is accomplished by one of four methods:
   1. Random plasma glucose ≥ 200 plus symptoms of diabetes (polyuria, polydipsia, unexplained weight loss)
   2. Fasting plasma glucose ≥126 (fasting means no caloric intake for 8 hours)
   3. A1C equal to or greater than 6.5%
   4. Two – hour plasma glucose > 200 during an oral glucose tolerance Test (OGTT) performed under World Health Organization (WHO) standards with a glucose load containing 75 g anhydrous glucose dissolved in water.

Methods 2 through 4 must be confirmed with a second reading on a subsequent day. It is preferable to use the same method for the second test. **The diagnosis of Impaired Fasting Glucose is made on the basis of a fasting Glucose of 100 to 125, or by A1C of 5.7 to 6.4%. These individuals should be re-tested for diabetes annually.**

II. Initial Evaluation

The initial evaluation should determine previous and current treatments, level of blood glucose control, the presence of diabetic complications, and the patients understanding of the disease. Documentation of the chronic illness will be documented in accordance with [OP 140137](#) entitled “Chronic Illness Management” and utilizing the “Chronic Illness Note/Physical Examination” form [DOC 140137A](#).

A. History
   1. Previous and current medications
   2. Diet
3. Exercise
4. Acute and chronic complications
5. Cardiovascular disease risk factors
6. Current symptoms

B. Examination
1. Complete set of vital signs (weight, temperature, pulse, respiration, blood pressure)
2. Dilated retinal examination
3. Thyroid palpation
4. Cardiovascular exam, including pulse
5. Foot exam (see section on foot evaluation)
6. Neurologic exam

C. Lab and Other Diagnostic Studies
1. HgbA₁C
2. Lipid profile
3. Complete metabolic profile
4. UA with urine albumin – to – creatinine ratio
5. EKG

III. Treatment
A. Indication for immediate Insulin therapy in type 2 diabetes:
1. Pregnancy
2. Surgery, infection, steroids
3. Marked weight loss and/or ketonuria with glucose >300 mg/dl
4. Hyperosmolar, non – ketotic state with glucose >600 mg/dl
5. * Diabetic Ketoacidosis requires hospitalization and fluid resuscitation.

B. Nutrition – In most people with type 2 diabetes, dietary recommendations are similar to those of the general population. Flexibility and achievable goals are the keys to dietary compliance. The Diet for Health from the state diet manual is adequate for most people.
C. Physical activity – unless contraindicated; 30 minutes of activity, most days of the week.

D. Aspirin 81 mg. p.o. daily, unless contraindicated – for primary prevention in patients at increased cardiovascular risk (10 year risk > 10%) which includes men > 50 years of age and women > 60 years of age with at least one (1) additional major risk factor (family history of CVD, HTN, smoking, dyslipidemia or albuminuria) – or as secondary prevention in patients with a history of CVD.

E. Atorvastatin 40-80 mg, unless contraindicated, for primary prevention in patients at increase CAD risk.

F. Control of blood pressure and lipids – refer to Medical Services Resource Manual (MSRM) 140137-04 entitled “Management of Hypertension”.

G. Eye care referral – for annual dilated retinal exam and treatment as indicated

H. Oral antidiabetic agents are preferred for type 2 diabetes unless the A1C > 11%, when insulin may be necessary, or when adequate control cannot be achieved with oral agents.

Metformin is a consensus first-line agent, (in the absence of recognized Contraindications).
Sulfonylureas, such as Glipizide and Glyburide, are considered second-line agents in the absence of recognized contraindications.

Other second-line agents include Pioglitazone, Sitagliptin, DPP-4 inhibitors, GLP1 receptor, SGLT2 inhibitors. These may also be used as third-line agents in addition to Metformin and Sulfonylurea. The choice of agent is dependent on specific patient characteristics. The GLP1 and SGLT2’s are very expensive and should be utilized on a case by case basis. We not only need to consider expense of medication while incarcerated, but the cost to the patient on discharge. These agents may be of value in cardiac patients not reaching goal despite other efforts.

<table>
<thead>
<tr>
<th>Name</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin (Glucophage)</td>
<td>1-2% A1C lowering&lt;br&gt;Does not cause hypoglycemia Gl side effects, which typically Resolve within 2 weeks.&lt;br&gt;Caution with CHF&lt;br&gt;Can promote beneficial weight loss.</td>
</tr>
<tr>
<td>Glipizide (Glucotrol)</td>
<td>1-2% A1C lowering&lt;br&gt;Risk of hypoglycemia Weight gain</td>
</tr>
<tr>
<td>Glyburide (DiaBeta, Micronase)</td>
<td>1-2% A1C lowering&lt;br&gt;High risk of hypoglycemia Weight gain</td>
</tr>
<tr>
<td>Pioglitazone (Actos)</td>
<td>0.5 – 1.4% A1C lowering&lt;br&gt;Fluid retention Potentially leads to heart failure.&lt;br&gt;Contraindicated in NYHA heart failure class III and IV Slow onset of action taking 6–12 weeks to see full effects Weight gain</td>
</tr>
</tbody>
</table>
Name | Comments |
--- | --- |
Sitagliptin (Januvia) | 0.5 – 0.8% A1C lowering Minimal side effects Potential to cause pancreatitis |
GLP-1 receptors | 0.5-1.4% A1C lowering. Pancreatitis warning. Weight loss, cardioprotective effect |
SGLT2-inhibitors | 0.5-.7%A1C reduction; cardiac/renal benefits; UTI’s/bone frx |

1. Insulin is the only antidiabetic agent approved for use in pregnancy. Metformin and Sitagliptin are pregnancy category B. Glipizide, glyburide, and pioglitazone are pregnancy category C.

2. Renal and Hepatic Dosing Adjustments:

<table>
<thead>
<tr>
<th>Name</th>
<th>Renal Dosing</th>
<th>Hepatic Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin</td>
<td>New guidelines use a GFR &lt; 30 as Contraindication for use of Metformin.</td>
<td>Contraindicated in hepatic failure or heart failure due to risk of lactic acidosis. (Hold for contrast radiology tests)</td>
</tr>
<tr>
<td>Glipizide</td>
<td>Not recommended when creatinine clearance (CrCl) &lt; 10</td>
<td>Initial dosage should be 2.5 mg/day in the presence of hepatic impairment.</td>
</tr>
<tr>
<td>Glyburide</td>
<td>Not recommended if CrCl is &lt; 50.</td>
<td>Use conservative initial and maintenance doses. Avoid use in severe disease.</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>No adjustment necessary.</td>
<td>Do not start pioglitazone if the patient exhibits active liver disease or if ALT &gt; 2.5 times the upper limit of normal. Discontinue pioglitazone if ALT &gt; 3 times the upper limit of normal or if jaundice is present.</td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>No adjustment required if CrCL &gt; 50. 50 mg. once daily if CrCl &gt; 30 to &lt; 50</td>
<td>No adjustment required if mild to moderate impairment (Child – Pugh score 7- 9). Not studied in severe impairment. (Child-Pugh score &gt;9)</td>
</tr>
<tr>
<td></td>
<td>or if serum creatinine &gt; 1.7 to &lt; 3 in males, and &gt; 1.5 to &lt; 2.5 in females.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25 mg once daily if CrCl &lt; 30 or if serum Creatinine &gt; 3 in males or &gt; 2.5 in females.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25 mg once daily (without regard to timing of dialysis), if Patient on hemodialysis or peritoneal dialysis.</td>
<td></td>
</tr>
</tbody>
</table>
3. The dose should be increased every 1 – 2 weeks for Metformin, Glipizide, and Glyburide and every 6 – 12 weeks for Pioglitazone until satisfactory glycemic control or maximum dose is reached.

4. If glycemic control is not achieved on maximum monotherapy, add an agent from the other class (sulfonylurea, metformin, or actos).

I. Insulin – In Type 2 Diabetics, if glycemic control is not achieved with maximum doses of oral agents, or if the baseline A1C is > 11%, it is necessary to begin insulin therapy. Insulin can be used alone or as an adjunct to oral agents with the exception of insulin secretagogues, such as sulfonylureas.

1. A bedtime dose of insulin, starting at 0.1 to 0.3 u/kg, can be added to metformin without changing the dose of metformin.

2. Frequent use of “sliding scale” insulin is problematic and indicates a need to adjust routine diabetes therapy. Short acting sliding scale insulin should be used only briefly for acute dynamic concurrent illness management and have no role in chronic dosing regimens.

3. Insulin choices are several and include long acting or basal insulin (Lantus/Levemir), intermediate acting insulin’s (NPH), short acting insulin’s (regular), rapid acting insulin’s (Humalog), and combinations (NPH + Regular, Lantus + regular or Humalog, and 70/30 NPH-Regular). Practitioners should have familiarity with the advantages of each. The use of Lantus or Levemir needs to be assessed, appropriately justified, and approved on a case-by-case basis. Waiting times for insulin and meals should be considered with the use of rapid acting insulin (Humalog).

J. Management of Complications

1. Nephropathy - treatment of microalbuminuria includes aggressive glycemic and blood pressure control, and use of an ACE inhibitor or ARB. In patients with creatinine > 1.5 or nephrotic range proteinuria (> 3gm/day) nephrology consult is indicated.


3. Foot lesions – see Section VI.

4. Neuropathy – see Section VI.
IV. Goals of Therapy

A. HgbA1C < 7.0%

Correlation between A1C level and mean plasma glucose levels

<table>
<thead>
<tr>
<th>A1C (%)</th>
<th>Mean plasma glucose mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>126</td>
</tr>
<tr>
<td>7</td>
<td>154</td>
</tr>
<tr>
<td>8</td>
<td>183</td>
</tr>
<tr>
<td>9</td>
<td>212</td>
</tr>
<tr>
<td>10</td>
<td>240</td>
</tr>
<tr>
<td>11</td>
<td>269</td>
</tr>
<tr>
<td>12</td>
<td>298</td>
</tr>
</tbody>
</table>

For most patients with type 2 diabetes, A1C is superior to FSBS for monitoring of glycemic control.

B. Fingerstick Blood Sugar

1. Before meals – 70 to 130

   2 hour PC - < 180

   FSBS Monitoring is most useful for patients with insulin dependent diabetes, who are experiencing labile glycemic control or symptomatic hypoglycemia.

C. Blood Pressure

1. <130/80 (<130 systolic and <80 diastolic)

2. Aggressive blood pressure control has an impact on renal preservation which is comparable to glycemic control.

D. Lipids

1. Total cholesterol <200 mg/dl

2. LDL cholesterol 50% reduction with statin

3. Triglycerides <150mg/dl

E. Patient Education

If the patient meets A and B above without medications for diabetes for 6 months a provider can discharge them from chronic clinic enrollment.
V. Routine Follow-Up

Once goals of therapy have been reached and the patient is stable, routine follow-up in chronic clinic should be arranged as follows:

A. Chronic Clinic Visit

1. Assess treatment regimen
2. Blood sugar results / HgbA1C results
3. Current medications – compliance, side effects
4. Hypoglycemic reactions
5. Symptoms of complications (visual, neurovascular, foot problems)
6. Physical exam
   a. Weight, blood pressure, temperature, pulse, respiration
   b. Foot exam
7. Categorize in accordance with “Severity Classification of Common Chronic Illness” (OP 140137, Attachment A).

B. Annually

1. History and physical exam, including funduscopic exam. Refer to optometrist as indicated
2. Laboratory
   a. Urinalysis (or dipstick)
   b. Urine albumin-to-creatinine ratio (for microalbuminuria), if UA protein is negative and patient is not on an ACE inhibitor.
      
      Urine Albumin-to-Creatinine Ratio

<table>
<thead>
<tr>
<th>Category</th>
<th>Spot Collection (ug/mg/creatinine)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt; 30</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>30-299</td>
</tr>
<tr>
<td>Marco (clinical) albuminuria</td>
<td>&gt;300</td>
</tr>
</tbody>
</table>

   c. Complete metabolic profile, including lipid profile
   d. Oral exam by provider with referral to dental as needed
C. Vaccines
   1. Influenza (annually)
   2. Pneumovax (revaccination is recommended only if the patient received a first dose prior to age 65. Give a second dose at or after age 65 only when 5 or more years have elapsed since the previous dose).

VI. Foot Care in People with Diabetes
A. Exam
   1. Skin exam – calluses, ulcers, pigment changes, cellulitis
   2. Joint mobility and deformity
   3. Vascular status – pulses, capillary refill, hair distribution
   4. Neurological status – numbness, burning, stinging; sensory exam
B. Prevention of High-Risk Conditions
   1. Smoking cessation
   2. Glycemic control
C. Management of High-Risk Conditions
   1. Neuropathy – amitriptyline, gabapentin, carbamazepine, cymbalta, well-cushioned walking shoes (available through canteen), and avoidance of hazards (scalding, lacerations, puncture wounds). Intensify glycemic control.
   2. Calluses – can be trimmed with scalpel by a provider or pumice stone by nursing.
   3. Bony deformities (e.g. hammer toes, bunions) – may require extra-wide or extra-depth shoe or support shoes (available through property). Severe deformities (e.g. charcot, amputation) may need custom shoes.
   4. Vasculopathy – symptoms of claudication may necessitate vascular referral; mild symptoms may respond to aspirin or platelet inhibitor therapy, and smoking cessation.
   5. Minor skin conditions should be treated to prevent more serious complications.
VII. References

OP-140137 entitled "Chronic Illness Management"


VIII. Action

The chief medical officer, Office of Medical Services will be responsible for compliance with this procedure.

Any exceptions to this procedure will require prior written approval from the director.

This procedure will be effective as indicated.


Distribution: Office of Medical Services Resource Manual

Referenced Forms  Title  Located In

<table>
<thead>
<tr>
<th>Referenced Forms</th>
<th>Title</th>
<th>Located In</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOC 140137 A</td>
<td>“Chronic Illness Note/Physical Examination”</td>
<td>OP-140137</td>
</tr>
</tbody>
</table>

Attachments

<table>
<thead>
<tr>
<th>Attachments</th>
<th>Title</th>
<th>Located In</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attachment A</td>
<td>“Severity Classification of Common Chronic Illness”</td>
<td>OP-140137</td>
</tr>
</tbody>
</table>